TrialJournal for immunotherapy of cancer2022

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.

Yuan-Yuan Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.